{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T03:11:31Z","timestamp":1784862691084,"version":"3.55.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.survophthal.2019.02.007","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T06:46:15Z","timestamp":1550817975000},"page":"380-400","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Pharmacologic therapy of mycotic keratitis"],"prefix":"10.1016","volume":"64","author":[{"given":"Pranita","family":"Sahay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Nagpal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prafulla K.","family":"Maharana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Gelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeewan S.","family":"Titiyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib1","first-page":"173","article-title":"Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study","volume":"49","author":"Agarwal","year":"2001","journal-title":"Indian J Ophthalmol"},{"issue":"28","key":"10.1016\/j.survophthal.2019.02.007_bib2","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1039\/C7NR00922D","article-title":"Condition responsive nanoparticles for managing infection and inflammation in keratitis","volume":"9","author":"Ahsan","year":"2017","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICO.0b013e31825e83bf","article-title":"Report of the Eye Bank Association of America medical advisory board subcommittee on fungal infection after corneal transplantation","volume":"32","author":"Aldave","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2019.02.007_bib4","unstructured":"Altun A, Kurna SA, Sengor T, et\u00a0al. Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs. Case Reports in Ophthalmological Medicine."},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib5","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/j.1442-9071.2010.02473.x","article-title":"Voriconazole versus natamycin as primary treatment in fungal corneal ulcers","volume":"39","author":"Arora","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib6","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10384-015-0397-x","article-title":"Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis","volume":"59","author":"Bae","year":"2015","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2174\/138920009788898019","article-title":"Amphotericin B and its new derivatives - mode of action","volume":"10","author":"Baginski","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib8","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib9","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archopht.1973.01000050404016","article-title":"Subconjunctival nodules after Amphotericin B injection: medical therapy for Aspergillus Corneal ulcer","volume":"90","author":"Bell","year":"1973","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajo.2006.07.033","article-title":"Topical and oral voriconazole in the treatment of fungal keratitis","volume":"143","author":"Bunya","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.007_bib11","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4103\/0301-4738.120213","article-title":"Successful treatment of Fusarium keratitis after photo refractive keratectomy","volume":"61","author":"Cavallini","year":"2013","journal-title":"Indian J Ophthalmol"},{"issue":"1-2","key":"10.1016\/j.survophthal.2019.02.007_bib12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijpharm.2014.10.035","article-title":"Corneal targeted nanoparticles for sustained natamycin delivery and their PK\/PD indices: an approach to reduce dose and dosing frequency","volume":"477","author":"Chandasana","year":"2014","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.007_bib13","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1167\/iovs.10-6935","article-title":"A\u00a0prototype antifungal contact lens","volume":"52","author":"Ciolino","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0378-5173(96)04473-0","article-title":"Amphotericin B eye drops as a lipidic emulsion","volume":"137","author":"Cohen","year":"1996","journal-title":"Int J Pharmaceutics"},{"key":"10.1016\/j.survophthal.2019.02.007_bib15","first-page":"279","article-title":"Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells","volume":"17","author":"Contreras-Ruiz","year":"2011","journal-title":"Mol Vis"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.007_bib17","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1093\/ndt\/gfg363","article-title":"Dosing guidelines for fluconazole in patients with renal failure","volume":"18","author":"Cousin","year":"2003","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1128\/AAC.50.3.917-921.2006","article-title":"Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi","volume":"50","author":"Cuenca-Estrella","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003088-198814010-00002","article-title":"Clinical pharmacokinetics of ketoconazole","volume":"14","author":"Daneshmend","year":"1988","journal-title":"Clin Pharm"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.007_bib20","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JCM.41.8.3623-3626.2003","article-title":"Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi","volume":"41","author":"Diekema","year":"2003","journal-title":"J\u00a0Clin Microbiol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib21","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1016\/j.actbio.2010.04.013","article-title":"Functionalization of acrylic hydrogels with alpha-, beta- or gamma-cyclodextrin modulates protein adsorption and antifungal delivery","volume":"6","author":"Dos","year":"2010","journal-title":"Acta Biomater"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/ICO.0000000000000869","article-title":"Report of the Eye Bank Association of America Medical Review Subcommittee on Adverse Reactions Reported From 2007 to 2014","volume":"35","author":"Edelstein","year":"2016","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2019.02.007_bib23","first-page":"377","article-title":"Aqueous pores created in thin lipid membranes by the polyene antibiotics nystatin and amphotericin B","volume":"2","author":"Finkelstein","year":"1973","journal-title":"Membranes"},{"key":"10.1016\/j.survophthal.2019.02.007_bib24","first-page":"CD004241","article-title":"Medical interventions for fungal keratitis","volume":"4","author":"FlorCruz","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1590\/S0004-27492006000300028","article-title":"Use of oral voriconazole as adjunctive treatment of severe cornea fungal infection: case report","volume":"69","author":"Freda","year":"2006","journal-title":"Arq Bras Oftalmol"},{"key":"10.1016\/j.survophthal.2019.02.007_bib26","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1080\/08982104.2016.1224899","article-title":"Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy","volume":"27","author":"Fu","year":"2017","journal-title":"J\u00a0Liposome Res"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.007_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/archopht.123.12.1721","article-title":"Intracorneal injection of amphothericin B for recurrent fungal keratitis and endophthalmitis","volume":"123","author":"Garcia-Valenzuela","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib28","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib29","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1128\/AAC.49.4.1359-1363.2005","article-title":"Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model","volume":"49","author":"Goldblum","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In\u00a0vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"Gonz\u00e1lez","year":"2005","journal-title":"Med Mycol"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib31","first-page":"241","article-title":"Voriconazole: the newest triazole antifungal agent","volume":"16","author":"Greer","year":"2003","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib32","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/phar.1533","article-title":"Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole","volume":"35","author":"Guarascio","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib33","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1203475415574970","article-title":"The Rise and Fall of Oral Ketoconazole","volume":"19","author":"Gupta","year":"2015","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/0974-9233.95271","article-title":"Combination of intracameral and intrastromal voriconazole in the treatment of recalcitrant Acremonium fungal keratitis","volume":"19","author":"Haddad","year":"2012","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archopht.122.1.42","article-title":"Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans","volume":"122","author":"Hariprasad","year":"2004","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00003226-199207000-00011","article-title":"Intraocular penetration of ketoconazole in rabbits","volume":"11","author":"Hemady","year":"1992","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2019.02.007_bib37","first-page":"3436415","article-title":"A\u00a0Combination of Intrastromal and Intracameral Injections of Amphotericin B in the Treatment of Severe Fungal Keratitis","volume":"2016","author":"Hu","year":"2016","journal-title":"J\u00a0Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib38","doi-asserted-by":"crossref","first-page":"6464","DOI":"10.1021\/acsnano.6b00601","article-title":"A\u00a0Hydrogel-Based hybrid theranostic contact lens for fungal keratitis","volume":"10","author":"Huang","year":"2016","journal-title":"ACS Nano"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib39","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0002-9394(14)78302-3","article-title":"Oral ketoconazole therapy for keratomycosis","volume":"95","author":"Ishibashi","year":"1983","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib40","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s11095-014-1586-x","article-title":"Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jcrs.2007.09.031","article-title":"Use of voriconazole in fungal keratitis","volume":"34","author":"Jones","year":"2008","journal-title":"J\u00a0Cataract Refract Surg"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1592\/phco.27.1.53","article-title":"Micafungin: a new echinocandin antifungal","volume":"27","author":"Joseph","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ijpharm.2015.08.088","article-title":"Lipid-polyethylene glycol based nano-ocular formulation of ketoconazole","volume":"495","author":"Kakkar","year":"2015","journal-title":"Int J Pharm"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib44","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/bjophthalmol-2014-305412","article-title":"Intrastromal voriconazole for deep recalcitrant fungal keratitis: a case series","volume":"99","author":"Kalaiselvi","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/01.ico.0000151539.92865.3e","article-title":"Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis","volume":"24","author":"Kalavathy","year":"2005","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/jop.2012.0232","article-title":"Dendrimer nanoparticles for ocular drug delivery","volume":"29","author":"Kambhampati","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib47","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00003226-200110000-00009","article-title":"Intracameral amphotericin B: initial experience in severe keratomycosis","volume":"20","author":"Kaushik","year":"2001","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tox.2009.01.008","article-title":"Intracameral voriconazole: In\u00a0vitro safety for human ocular cells","volume":"258","author":"Kernt","year":"2009","journal-title":"Toxicology"},{"key":"10.1016\/j.survophthal.2019.02.007_bib49","article-title":"Nanoparticles: Properties, applications and toxicities","author":"Khan","year":"2017","journal-title":"Arabian J Chem"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib50","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/jac\/33.2.203","article-title":"Administering amphotericin B--a practical approach","volume":"33","author":"Khoo","year":"1994","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib51","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.biomaterials.2009.10.031","article-title":"Ultrapure chitosan oligomers as carriers for corneal gene transfer","volume":"31","author":"Klausner","year":"2010","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib52","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1021\/mp200155t","article-title":"Expression of MUC5AC in Ocular Surface Epithelial Cells Using Cationized Gelatin Nanoparticles","volume":"8","author":"Konat Zorzi","year":"2011","journal-title":"Mol Pharmaceutics"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib53","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00003226-200210000-00004","article-title":"Intracameral amphotericin B injection in the management of deep keratomycosis","volume":"21","author":"Kuriakose","year":"2002","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib54","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1128\/JCM.00610-08","article-title":"Vitro Natamycin Susceptibility of Ocular Isolates of Fusarium and Aspergillus Species: Comparison of Commercially Formulated Natamycin Eye Drops to Pharmaceutical-Grade Powder","volume":"46","author":"Lalitha","year":"2008","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib55","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/j.1552-4604.1997.tb04332.x","article-title":"Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers","volume":"37","author":"Lange","year":"1997","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib56","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1021\/ie0507934","article-title":"Modeling ophthalmic drug delivery by soaked contact lenses","volume":"45","author":"Li","year":"2006","journal-title":"Ind Eng Chem Res"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib57","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In\u00a0vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.007_bib58","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00004397-199803840-00011","article-title":"Fungal keratitis","volume":"38","author":"Mabon","year":"1998","journal-title":"Int Ophthalmol Clin"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib60","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4103\/0301-4738.185592","article-title":"Recent advances in diagnosis and management of Mycotic Keratitis","volume":"64","author":"Maharana","year":"2016","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jop.2010.0005","article-title":"Topical amphotericin B and subconjunctival injection of fluconazole (combination therapy) versus topical amphotericin B (monotherapy) in treatment of keratomycosis","volume":"26","author":"Mahdy","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.007_bib62","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/myc.12822","article-title":"Fungal keratitis: An overview of clinical and laboratory aspects","volume":"61","author":"Mahmoudi","year":"2018","journal-title":"Mycoses"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib63","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.ico.0000154390.28254.54","article-title":"Successful topical application of a new antifungal agent, micafungin, in the treatment of refractory fungal corneal ulcers: report of three cases and literature review","volume":"24","author":"Matsumoto","year":"2005","journal-title":"Cornea"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib64","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1136\/bjo.2010.191734","article-title":"The comparison of solitary topical micafungin or fluconazole application in the treatment of Candida fungal keratitis","volume":"95","author":"Matsumoto","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib65","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1089\/jop.2014.0004","article-title":"Safety and efficacy of intrastromal injection of 5% natamycin in experimental fusarium keratitis","volume":"30","author":"Mimouni","year":"2014","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib66","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/ICO.0b013e318233f0a8","article-title":"Intracameral and topical voriconazole for fungal corneal endoexudates","volume":"31","author":"Mittal","year":"2012","journal-title":"Cornea"},{"issue":"1-2","key":"10.1016\/j.survophthal.2019.02.007_bib67","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2007.04.028","article-title":"Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability","volume":"344","author":"Morand","year":"2007","journal-title":"Int J Pharm"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib68","doi-asserted-by":"crossref","first-page":"601","DOI":"10.4103\/1110-2098.198726","article-title":"Topical amphotericin B versus subconjunctival fluconazole injection in the management of fungal keratitis","volume":"29","author":"Mottawea Eman","year":"2016","journal-title":"Menoufia Med J"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1590\/S0034-72802013000200014","article-title":"Antifungals in eye infections: drugs and routes of administration","volume":"72","author":"M\u00fcller","year":"2013","journal-title":"Rev Bras Oftalmol"},{"key":"10.1016\/j.survophthal.2019.02.007_bib70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2147\/OPTH.S135112","article-title":"Combined intrastromal injection of amphotericin B and topical fluconazole in the treatment of resistant cases of keratomycosis: a retrospective study","volume":"11","author":"Nada","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib71","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1128\/AAC.00060-12","article-title":"Stability of extemporaneously prepared 0.5-percent caspofungin eye drops: a potential cost-savings exercise","volume":"56","author":"Neoh","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib72","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1345\/aph.1P586","article-title":"Treatment of Alternaria keratitis with intrastromal and topical caspofungin in combination with intrastromal, topical, and oral voriconazole","volume":"45","author":"Neoh","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib73","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.idc.2015.10.012","article-title":"Antifungal agents: Spectrum of activity, pharmacology, and clinical indications","volume":"30","author":"Nett","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.survophthal.2019.02.007_bib74","first-page":"1075","article-title":"Ineffectiveness of intrastromal voriconazole for filamentous fungal keratitis","volume":"8","author":"Niki","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib75","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archopht.1990.01070090108050","article-title":"Ocular uptake of fluconazole following oral administration","volume":"108","author":"O'Day","year":"1990","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib76","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/00003226-199109000-00010","article-title":"Toxicity and pharmacokinetics of subconjunctival amphotericin B. An experimental study","volume":"10","author":"O'Day","year":"1991","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib77","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/ICO.0b013e3180553b9d","article-title":"Efficacy of topical caspofungin in experimental fusarium keratitis","volume":"26","author":"Ozturk","year":"2007","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib78","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/17425240902762818","article-title":"Chitosan nanoparticles for drug delivery to the eye","volume":"6","author":"Paolicelli","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib79","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2011.11.034","article-title":"Voriconazole for fungal corneal ulcers","volume":"119","author":"Parchand","year":"2012","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib80","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1089\/jop.2016.0186","article-title":"Echinocandins in Ocular Therapeutics","volume":"33","author":"Patil","year":"2017","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.survophthal.2019.02.007_bib81","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1016\/j.biomaterials.2010.01.113","article-title":"Extended delivery of hydrophilic drugs from silicone-hydrogel contact lenses containing vitamin E diffusion barriers","volume":"31","author":"Peng","year":"2010","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib82","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1128\/JCM.43.5.2163-2167.2005","article-title":"Global Trends in the Antifungal Susceptibility of Cryptococcus neoformans (1990 to 2004)","volume":"43","author":"Pfaller","year":"2005","journal-title":"J\u00a0Clin Microbiol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib83","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/OPX.0000000000000760","article-title":"Release of Fluconazole from Contact Lenses Using a Novel In\u00a0Vitro Eye Model","volume":"93","author":"Phan","year":"2016","journal-title":"Optom Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib84","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1517\/17425247.2014.882315","article-title":"Contact lenses for antifungal ocular drug delivery: a review","volume":"11","author":"Phan","year":"2014","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib85","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jac\/dku355","article-title":"Antifungal drugs during pregnancy: an updated review","volume":"70","author":"Pilmis","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib86","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1073\/pnas.061562898","article-title":"Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors","volume":"98","author":"Podust","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3-4","key":"10.1016\/j.survophthal.2019.02.007_bib87","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000221854","article-title":"Mode of action of 5-fluorocytosine and mechanisms of resistance","volume":"21","author":"Polak","year":"1975","journal-title":"Chemotherapy"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib88","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bjo.87.10.1235","article-title":"A\u00a0randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis","volume":"87","author":"Prajna","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib89","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1001\/jamaophthalmol.2013.1497","article-title":"The mycotic ulcer treatment trial: a randomized trial comparing natamycin vs voriconazole","volume":"131","author":"Prajna","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.007_bib90","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1001\/jamaophthalmol.2016.4096","article-title":"Effect of Oral Voriconazole on Fungal Keratitis in the Mycotic Ulcer Treatment Trial II (MUTT II): A Randomized Clinical Trial","volume":"134","author":"Prajna","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib91","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/archophthalmol.2010.102","article-title":"Comparison of natamycin and voriconazole for the treatment of fungal keratitis","volume":"128","author":"Prajna","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib92","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ajo.2008.02.023","article-title":"Evaluation of intrastromal injection of voriconazole as a therapeutic adjunctive for the management of deep recalcitrant fungal keratitis","volume":"146","author":"Prakash","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.007_bib93","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1128\/AAC.46.8.2546-2553.2002","article-title":"Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens","volume":"46","author":"Purkins","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.survophthal.2019.02.007_bib94","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib95","first-page":"597","article-title":"Natamycin in the treatment of fungal keratitis: a systematic review and Meta-analysis","volume":"8","author":"Qiu","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib96","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000254566","article-title":"Corneal and aqueous humor concentrations of amphotericin B using three different routes of administration in a rabbit model","volume":"43","author":"Qu","year":"2010","journal-title":"Ophthalmic Res"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib97","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/APO.0000000000000035","article-title":"Topical 5% natamycin with oral ketoconazole in filamentous fungal keratitis: A Randomized Controlled Trial","volume":"4","author":"Rajaraman","year":"2015","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.survophthal.2019.02.007_bib98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: Mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib99","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1128\/AAC.42.5.1057","article-title":"Vitro Activities of Terbinafine against Cutaneous Isolates of Candida albicans and Other Pathogenic Yeasts","volume":"42","author":"Ryder","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.007_bib100","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1345\/aph.19237","article-title":"Voriconazole: A New Triazole Antifungal","volume":"34","author":"Sabo","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.survophthal.2019.02.007_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2018-226498","article-title":"Periocular contact dermatitis with use of topical voriconazole 1% in mycotic keratitis","volume":"2018","author":"Sahay","year":"2018","journal-title":"BMJ Case Rep"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.007_bib102","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1128\/AAC.41.11.2492","article-title":"A\u00a0new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei","volume":"41","author":"Sanati","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib103","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/AAC.31.1.6","article-title":"Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis","volume":"31","author":"Savani","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib104","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1159\/000221880","article-title":"Experimental and clinical studies of 5-fluorocytosine activity in Candida ocular infections. I. In\u00a0vitro activity of 5-fluorocytosine on Candida species isolated from ocular infections","volume":"21","author":"Segal","year":"1975","journal-title":"Chemotherapy"},{"issue":"11","key":"10.1016\/j.survophthal.2019.02.007_bib105","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3109\/02713683.2010.506968","article-title":"Single and multidose ocular kinetics and stability analysis of extemporaneous formulation of topical voriconazole in humans","volume":"35","author":"Senthilkumari","year":"2010","journal-title":"Curr Eye Res"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib106","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/bjo.2009.169607","article-title":"Geographic Variations in Microbial Keratitis: An analysis of the Peer-Reviewed Literature","volume":"95","author":"Shah","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib107","first-page":"257","article-title":"Therapeutic efficacy of intracameral amphotericin B injection for 60 patients with keratomycosis","volume":"3","author":"Shao","year":"2010","journal-title":"Int J Ophthalmol"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.007_bib108","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1136\/bjo.2010.192815","article-title":"Evaluation of intrastromal voriconazole injection in recalcitrant deep fungal keratitis: case series","volume":"95","author":"Sharma","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib109","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ophtha.2012.09.023","article-title":"Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis","volume":"120","author":"Sharma","year":"2013","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib110","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/ICO.0000000000001781","article-title":"Management Algorithm for Fungal Keratitis: The TST (Topical, Systemic, and Targeted Therapy) Protocol","volume":"38","author":"Sharma","year":"2018","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib111","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3109\/09273948.2015.1057597","article-title":"Evaluation of intracameral Amphotericin B in the management of fungal keratitis: Randomized Controlled Trial","volume":"24","author":"Sharma","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"issue":"12","key":"10.1016\/j.survophthal.2019.02.007_bib112","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/ICO.0000000000001365","article-title":"Comparison of oral voriconazole versus oral ketoconazole as an adjunct to topical natamycin in severe fungal keratitis: A Randomized Controlled Trial","volume":"36","author":"Sharma","year":"2017","journal-title":"Cornea"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib113","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ajo.2010.01.024","article-title":"Intracameral voriconazole injection in the treatment of fungal endophthalmitis resulting from keratitis","volume":"149","author":"Shen","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib114","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1128\/AAC.01125-08","article-title":"Pharmacokinetics of Intracameral Voriconazole Injection","volume":"53","author":"Shen","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.survophthal.2019.02.007_bib115","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/ICO.0b013e3182100993","article-title":"The effects of intrastromal voriconazole injection and topical voriconazole in the treatment of recalcitrant Fusarium keratitis","volume":"30","author":"Siatiri","year":"2011","journal-title":"Cornea"},{"key":"10.1016\/j.survophthal.2019.02.007_bib116","series-title":"Smolin and Thoft's The Cornea: Scientific Foundations and Clinical Practice","first-page":"420","author":"Smolin","year":"2005"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib117","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/bjo.86.7.829-a","article-title":"Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis","volume":"86","author":"Sponsel","year":"2002","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib118","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/eop.10.19","article-title":"Current efforts and the potential of nanomedicine in treating fungal keratitis","volume":"5","author":"Gratieri","year":"2010","journal-title":"Expert Rev Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib120","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1074\/jbc.M707821200","article-title":"Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane","volume":"283","author":"Te Welscher","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"6","key":"10.1016\/j.survophthal.2019.02.007_bib121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1755-3768.1994.tb04697.x","article-title":"Oral fluconazole therapy for keratomycosis","volume":"72","author":"Thakar","year":"1994","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib122","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1128\/AAC.00762-06","article-title":"Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis","volume":"51","author":"Thiel","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib123","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1439-0507.1988.tb03986.x","article-title":"Oral itraconazole therapy for mycotic keratitis","volume":"31","author":"Thomas","year":"1988","journal-title":"Mycoses"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib124","first-page":"197","article-title":"Oral ketoconazole in Keratomycosis","volume":"35","author":"Thomas","year":"1987","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1469-0691.12126","article-title":"Mycotic keratitis: epidemiology, diagnosis and management","volume":"19","author":"Thomas","year":"2013","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"10.1016\/j.survophthal.2019.02.007_bib126","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1128\/AAC.34.10.2032","article-title":"Effect of oral antacid administration on the pharmacokinetics of oral fluconazole","volume":"34","author":"Thorpe","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.survophthal.2019.02.007_bib127","first-page":"711","article-title":"Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits","volume":"26","author":"Tremblay","year":"1985","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Supplement_3","key":"10.1016\/j.survophthal.2019.02.007_bib128","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1093\/clinids\/12.Supplement_3.S276","article-title":"Fluconazole and other zoles: Translation of in\u00a0vitro activity to in\u00a0vivo and clinical Efficacy","volume":"12","author":"Troke","year":"1990","journal-title":"Rev Infect Dis"},{"issue":"13","key":"10.1016\/j.survophthal.2019.02.007_bib129","first-page":"113","article-title":"Comparison of two antifungal agents, Natamycin and Micafungin, for Fungal Keratitis","volume":"45","author":"Trujillo","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib130","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICO.0b013e31818225f8","article-title":"Alternaria keratitis: clinical presentation and resolution with topical fluconazole or intrastromal voriconazole and topical caspofungin","volume":"28","author":"Tu","year":"2009","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.007_bib131","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/ICO.0000000000000192","article-title":"Intrastromal antifungal injection with secondary lamellar interface infusion for late-onset infectious keratitis after DSAEK","volume":"33","author":"Tu","year":"2014","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.survophthal.2019.02.007_bib132","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2006.10.048","article-title":"Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592)","volume":"143","author":"Tu","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib133","first-page":"147","article-title":"Fluconazole in the Management of Fungal Ocular Infections","volume":"208","author":"Urbak","year":"1994","journal-title":"OPH"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib134","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/BF00558308","article-title":"The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects","volume":"36","author":"Van Peer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/archophthalmol.2007.8","article-title":"Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans","volume":"126","author":"Vemulakonda","year":"2008","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2019.02.007_bib136","first-page":"512","article-title":"The Nanomedicine Revolution","volume":"37","author":"Ventola","year":"2012","journal-title":"PT"},{"issue":"1","key":"10.1016\/j.survophthal.2019.02.007_bib137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ophtha.2016.09.017","article-title":"Incidence and outcomes of positive donor corneoscleral rim fungal cultures after keratoplasty","volume":"124","author":"Vislisel","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.survophthal.2019.02.007_bib138","first-page":"744","article-title":"Observation of therapeutical effect of natamyc in fungal corneal ulcer","volume":"10","author":"Wang","year":"2010","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2019.02.007_bib139","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"4","key":"10.1016\/j.survophthal.2019.02.007_bib140","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/ICO.0b013e318030767e","article-title":"Efficacy of intracameral amphotericin B injection in the management of refractory keratomycosis and endophthalmitis","volume":"26","author":"Yilmaz","year":"2007","journal-title":"Cornea"},{"issue":"7","key":"10.1016\/j.survophthal.2019.02.007_bib141","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/ICO.0b013e31806c791e","article-title":"Therapeutic effect of intracameral amphotericin B injection in the treatment of fungal keratitis","volume":"26","author":"Yoon","year":"2007","journal-title":"Cornea"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717303387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717303387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:48:07Z","timestamp":1758541687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625717303387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":141,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0039625717303387"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic therapy of mycotic keratitis","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2019.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}